T-lymphocytes in bone marrow samples of children with acute lymphoblastic leukemia during and after chemotherapy might hamper PCR-based minimal residual disease studies.
- 26 July 2001
- journal article
- research article
- Published by Springer Nature in Leukemia
- Vol. 15 (8) , 1301-3
- https://doi.org/10.1038/sj.leu.2402184
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Regenerating normal B‐cell precursors during and after treatment of acute lymphoblastic leukaemia: implications for monitoring of minimal residual diseaseBritish Journal of Haematology, 2000
- T cell receptor gamma (TCRG) gene rearrangements in T cell acute lymphoblastic leukemia reflect ‘end-stage’ recombinations: implications for minimal residual disease monitoringLeukemia, 2000
- Rapid, multifluorescent TCRG Vγ and Jγ typing: application to T cell acute lymphoblastic leukemia and to the detection of minor clonal populationsLeukemia, 2000
- BIOMED-1 Concerted Action report: Flow cytometric characterization of CD7+ cell subsets in normal bone marrow as a basis for the diagnosis and follow-up of T cell acute lymphoblastic leukemia (T-ALL)Leukemia, 2000
- Primers and protocols for standardized detection of minimal residual disease in acute lymphoblastic leukemia using immunoglobulin and T cell receptor gene rearrangements and TAL1 deletions as PCR targets Report of the BIOMED-1 CONCERTED ACTION: Investigation of minimal residual disease in acute leukemiaLeukemia, 1999
- Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhoodThe Lancet, 1998